Our study adopted approaches like those used for clinical gene therapy, such as using lentiviruses to deliver CRISPR/Cas9 genes, targeting leukemia cells with the native Ph chromosome, optimizing the ABL genomic editing sequences and evaluating cancer efficacy in an animal model of systemic leukemia. Here, ABL1 is linked to cancer.